Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants

Coronavirus Jun 30, 2022 10:10PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

By Michael Erman and Manas Mishra

(Reuters) -The U.S. Food and Drug Administration on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.

If authorized, the changes would mark the first major retooling of COVID vaccines, but also could slow their rollout as the FDA has recommended a design somewhat different from what the companies had already tested and started producing.

The FDA will not require new studies testing the BA.4/BA.5 shots in humans to be completed for authorization, a top agency official told Reuters, similar to how annual changes to flu vaccines are handled.

"In a sense, we are chasing the virus, just as we do with influenza, and how close we can get to the variants that are prominent at the time, we'll have to wait and see," said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center, adding that redesigned vaccines could provide better protection than current ones.

The FDA said companies would not need to change the vaccine for the primary vaccination series, saying the coming year will be "a transitional period when this modified booster vaccine may be introduced."

The new booster shots would be bivalent vaccines, targeting both the original virus as well as the Omicron subvariants.

The decision follows a recommendation by the agency's outside advisers to change the vaccine design this fall to combat more prevalent versions of the coronavirus.

BA.4 and BA.5 are estimated to account for more than 50% of U.S. infections, according the U.S. Centers for Disease Control and Prevention, and have also become dominant elsewhere.

The FDA said on Thursday that it hoped the modified vaccines could be used in early to mid-fall.

Scientists have suggested redesigned boosters could spur a broader range of immune responses that might also protect against future variants that may emerge.

"Predicting the future with COVID-19 in particular is hazardous, because COVID has faked us out on a number of occasions," Schaffner said.

DIFFERENT STRATEGIES FOR DIFFERENT COUNTRIES

Regulators from other countries are seriously considering using new boosters based on the BA.1 Omicron variant that caused the massive surge in cases last winter, top FDA official Dr. Peter Marks said in an interview.

"Some may want a vaccine more rapidly. That (vaccine) is going to be available more rapidly," Marks said, after a meeting of international regulators on Thursday.

Advisers to the World Health Organization preferred BA.1-based boosters, arguing that the variant is more distinct and could generate a broader response than the more recently circulating subvariants.

Pfizer Inc (NYSE:PFE) with partner BioNTech SE (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) Inc have been testing versions of their vaccines modified to combat the BA.1 Omicron variant.

Although they have said those vaccines generated a good immune response against BA.1 and the more recently circulating variants, they did see a lower response against BA.4 and BA.5.

The companies had already been manufacturing their BA.1 vaccines, and said on Tuesday switching to a BA.4/BA.5 design could delay their introduction.

Pfizer/BioNTech, which on Wednesday announced a $3.2 billion contract to supply more COVID vaccine doses to the United States, said they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution by the first week of October.

Moderna said it would be late October or early November before its modified vaccine is ready.

The FDA has directed manufacturers to launch clinical trials to study the BA.4/5 vaccines, but said they would evaluate data on their previous BA.1-based vaccines to support authorization of the retooled shots.

Marks said data from the new trial will be important to gauge the continued effectiveness of the boosters against new variants that may arise.

US FDA wants COVID boosters targeting Omicron BA.4, BA.5 subvariants
 

Related Articles

China to discourage abortions to boost low birth rate
China to discourage abortions to boost low birth rate By Reuters - Aug 16, 2022

By Farah Master and Albee Zhang HONG KONG (Reuters) - China will discourage abortions and take steps to make fertility treatment more accessible as part of efforts to boost one of...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
William Smith
William Smith Jul 10, 2022 11:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
There is already vaccines that work against the mentioned variants, but since they weren't developed by and aren't controlled by big pharma the FDA wont approve them.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email